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Abstract
Chromosomal sex determination is a widely distributed strategy in nature. In the most classic
scenario, one sex is characterized by a homologue pair of sex chromosomes, while the other
includes two morphologically and functionally distinct gonosomes. In mammalian diploid cells, the
female is characterized by the presence of two identical X chromosomes, while the male features
an XY pair, with the Y bearing the major genetic determinant of sex, i.e. the SRY gene. In other
species, such as the fruitfly, sex is determined by the ratio of autosomes to X chromosomes.
Regardless of the exact mechanism, however, all these animals would exhibit a sex-specific gene
expression inequality, due to the different number of X chromosomes, a phenomenon inhibited by
a series of genetic and epigenetic regulatory events described as "dosage compensation". Since
adequate available data is currently restricted to worms, flies and mammals, while for other groups
of animals, such as reptiles, fish and birds it is very limited, it is not yet clear whether this is an
evolutionary conserved mechanism. However certain striking similarities have already been
observed among evolutionary distant species, such as Drosophila melanogaster and Mus musculus.
These mainly refer to a) the need for a counting mechanism, to determine the chromosomal
content of the cell, i.e. the ratio of autosomes to gonosomes (a process well understood in flies,
but still hypothesized in mammals), b) the implication of non-translated, sex-specific, regulatory
RNAs (roX and Xist, respectively) as key elements in this process and the location of similar
mediators in the Z chromosome of chicken c) the inclusion of a chromatin modification epigenetic
final step, which ensures that gene expression remains stably regulated throughout the affected
area of the gonosome. This review summarizes these points and proposes a possible role for
comparative genetics, as they seem to constitute proof of maintained cell economy (by using the
same basic regulatory elements in various different scenarios) throughout numerous centuries of
evolutionary history.
Background
The emergence and consequent prevalence of heterog-
amety as the dominant reproduction mechanism among
the eukaryotes, was soon followed by the appearance of a
genetic inequality issue that demanded to be dealt with.
As is now well established, the set of sex chromosomes
derived from an autosomal pair that has undergone a
lengthy evolutionary process of limited recombination,
degeneration and loss of gene function regarding one of
the two chromosomes of the initial set. This process
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resulted in the formation of a derivative, largely deficient
chromosome, usually denoted as Y (due to its shape in
mammals), contrary to its previous homologue, now
known as X. While it seems inevitable, therefore, that all
genes located on the differentiated X chromosome and
missing on the Y will have a two-fold level difference
between the two sexes, the fact remains that most of them
are not related to aspects of sexual dimorphism and hence
a difference in gene product levels would actually result in
a significant liability.
Dosage compensation is the term used to describe the
process of attempting to equalize the gene expression
between the different sets of sex chromosomes and seems
to become an increasingly interesting field of research.
There are many intriguing aspects to the phenomenon of
dosage compensation, not the least of them the notion
that several unrelated organisms seem to have independ-
ently devised similar mechanisms to achieve a certain
kind of global chromosome activity regulation that would
not interfere with the finely attuned control of individual
genes' expression. Though these mechanisms themselves
seem to differ at a first glance, a persistent repetition of
elements, such as the implication of regulatory RNA mol-
ecules, the effects on chromatin structure and their strong
dependence on autosomal versus X chromosome count-
ing elements (depending on the species, either already
proven or still hypothesized), require that we shed more
light in what lies further down the road.
Dosage compensation in Drosophila 
melanogaster
In the case of the common fruitfly, Drosophila mela-
nogaster, like several other species, sex is determined by
the presence of two X chromosomes versus a pair of X and
Y. However, whereas the Y chromosome contains very few
genes, mostly associated with male fertility, its counter-
part houses several different genes, that are essential for a
variety of functions. As a result, the process of dosage
compensation in Drosophila melanogaster appears to have
evolved, in fact, as an indispensable necessity for the con-
tinued development and survival of the species. This is
accomplished by practically doubling the expression of
every gene located on the single X chromosome in males,
through the assembly and association of an RNA and pro-
tein complex, also known as the DCC (Dosage Compen-
sation Complex) or compensasome (the latter term is
emphasizing the complex's combined action as a cellular
multi-molecular micro-machine, similar to other exam-
ples, including the apoptosome, inflammasome and pro-
teasome) [1].
The six protein components of the DCC, which include
the mle (maleless) [2,3], msl-1 (male-specific lethal) [4],
msl-2 [5], msl-3, mof (males absent on the first) [3] and jil-
1 products, when combined with the non-coding RNAs
roX1 and roX2 (RNA on the X) [6-8] form an active com-
plex which is localized on the X chromosome. Complex
formation is rapidly followed by enrichment with
H4Ac16, a specific histone isoform that has been
acetylated at lysine 16 and which leads to a change in
chromatin structure. Thus, the ultimate result of compen-
sasome constitution is an increased transcriptional activ-
ity of every gene located on the single male X
chromosome (opposite to mammalian X inactivation,
described later) [9-11] [see Figure 1].
Sex specific regulation of this mechanism is achieved by
the fact that all components of the DCC must be present
to allow it to bind and expand across the entire X chromo-
some. And while this has been validated for all six pro-
teins and the roX RNAs, it is msl-2 especially, and, to a
lesser degree, msl-1, that suppresses this mechanism in
females, since it has been established that the sex deter-
mining switch protein SXL, which is only present in
females, deregulates translation of msl-2  transcripts
[12,13].
Once male status has been established through sxl and
consequently msl-2, a complex mechanism that encom-
passes the assembly of the DCC and its binding to the X
chromosome is initiated. The core of the DCC predomi-
nantly consists of the MSL1 and MSL2 proteins, which
bind together and exhibit a weak interaction with circa 35
sites across the X chromosome. The latter are described in
the literature as chromatin entry sites. Two of these entry
sites correspond to the roX1 and roX2 genes as well [6,7].
Interestingly, the MLE protein, which is expressed in both
sexes, but only appears to participate in this process in
males, is necessary for the MSL1 and MSL2 proteins to fur-
ther interact with the roX RNAs [6,7]. Consequently, it is
assumed that MLE stabilizes the original complex and its
binding to the initial chromatin entry sites.
To complete compensasome activity in D. melanogaster,
the recruitment of additional proteins is necessary, since a
fully functional dosage compensation complex requires
the integration of the remaining three proteins previously
mentioned, i.e. MSL3, MOF and JIL1 kinase. MSL3 has
been known to be able to interact with chromatin,
whereas MOF displays H4 histone acetyltransferase activ-
ity [10]. Once the DCC has been fully assembled, it gains
the ability to interact with several more sites and can con-
sequently be located (expanded) across the entire X chro-
mosome.
The missing details of the mechanism that allows target-
ing the single X chromosome among the autosomes have
been a hot topic of intensive research recently. It was ini-
tially believed that the DCC could spread along in cis, ini-Reproductive Biology and Endocrinology 2008, 6:12 http://www.rbej.com/content/6/1/12
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tially interacting with chromatin around the 35–40
chromatin entry sites and thus, gradually covering the
entire chromosome [14,15]. This was supported by data
reporting that integration of a roX1 or roX2 gene, which
contains a chromatin entry site, to an autosome led to
hyper-transcription of neighboring autosomal genes, but
this adaptive reaction was limited only in the immediately
proximal area of the chromosome [16,17].
However, it was soon also discovered that inserting a part
of the X chromosome without a major entry site would
still attract the compensasome and result in epigenetic
chromatin modification, namely acetylation and hyper-
transcription. On the other hand, inserting a part of an
autosome into the X chromosome would usually display
dosage compensation effects at its connecting points, but
not the complete spreading that is normally observed
along the rest of the X chromosome [18].
Newly presented data has suggested that, instead of the
35–40 major chromatin entry sites alone, there may in
fact exist a wide population of chromatin entry sites with
varying affinity for the DCC [18-21]. According to this
theory, while high-affinity sites may suffice for the initia-
tion of the DCC in-cis spreading on their own, medium
and low level affinity sites may need to interact with sev-
eral mediators or even in combinations, to be successful
as additional binding positions for the DCC [19]. What
now remains to be seen is what exactly these varying entry
sites consist of.
(A) More recent findings imply that there are in fact several different classes of chromatin entry sites with varying affinity  towards the DCC Figure 1
(A) More recent findings imply that there are in fact several different classes of chromatin entry sites with varying affinity 
towards the DCC. (B1) When only the core proteins MSL1 and MSL2 are present, they are merely capable of weakly interact-
ing with each other and gathering around the ~35 sites that have been denoted as high-affinity entry sites. (B2) The addition of 
MLE and one of the two roX RNAs amplifies this interaction, but only the fully assembled complex (B3) can spread along the 
entire X chromosome by interacting with the rest of the entry sites in normal concentrations.Reproductive Biology and Endocrinology 2008, 6:12 http://www.rbej.com/content/6/1/12
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Besides targeting, further questions concerning dosage
compensation in the fruitfly still remain to be answered.
While it is true that, through the control of sxl, the absence
of MSL2 alone is responsible for the inhibition of the
DCC assembly in females, the rest of the compensasome
components seem to be present in females as well, dis-
playing a uniform low level association with all chromo-
somes [22]. The hypothesis that dosage compensation in
Drosophila doesn't simply concern X chromosome hyper-
translation, rather it may affect autosomal expression as
well under various alterations, also seems intriguing. For
example, achieving DCC assembly and targeting the pair
of X chromosomes in females does not result in their
hyper-transcription, but rather in autosomal gene down-
regulation [23]. Furthermore, the majority of authors
agree that histone acetylation of the X chromosome alone
does not seem to be sufficient to account for all attributes
of this phenomenon.
In addition, it has become apparent through more recent
studies that dosage compensation in Drosophila is a far
more dynamic mechanism than we may have imagined. It
seems, for example, that DCC binding can differ between
different cell types, with a distinct predilection for target-
ing transcriptionally active genes [24]. Furthermore, this
profile of DCC binding appears to be established during
early stages of development and afterwards, it shows only
minor differences, despite the extensive changes observed
in gene expression, promoting the hypothesis of an early
establishment of DCC binding [25]. The mechanism of
this interaction within the context of dosage compensa-
tion has yet to be established, although recent data point
towards the existence of target sequences within the cod-
ing regions of many genes that are only revealed in the
presence of the transcription machinery [26].
Finally, and more importantly, one cannot ignore the fact
that there are genes within the X chromosome, such as
Lsp-1α, which have homologues on the autosomes [27],
or the female-specific yolk protein genes [28], which seem
to escape the effects of dosage compensation. Others, such
as the runt gene, are dosage compensated post-transcrip-
tionally by SXL in females [29]. One theory attempting to
explain this controversial discovery postulated that this
may be the result of quantitative differences in the levels
of in trans acting autosomal transcription factors [22]. The
fact remains, however, that more light needs to be shed on
if and how this may be achieved.
Dosage compensation in other species: Many 
questions, no answers yet
Dosage compensation is thought to be a mechanism that
may, theoretically, be necessary for all species exhibiting
sexual dimorphism at a chromosomal level, since this
mechanism includes a differentiated expression of a cer-
tain number of genes in each sex. Evidently, the under-
standing of this procedure is directly associated with the
detailed description of the pathway of sex determination
and differentiation in the various species and, indeed,
progress in dosage compensation basic research has only
been observed in cases where sexual choice had been
already adequately understood and described at a molec-
ular level.
Advances in sex determination genetics, comparative biol-
ogy and reproductive physiology of reproduction have
revealed that chromosomal sex determination is a very
common process in nature, extending to various animals
of diverse evolutionary background, such as birds, fish,
amphibians, reptiles and, of course, mammals. In all the
above cases a pair of chromosomes is considered to be the
major determinant of sex, usually referred as gonosomes
or sex chromosomes. Should this pair be identical in the
female and differentiated in the male, the terminology XX,
XY is applied, deriving from the macroscopic description
of these chromosomes in eutherian mammals. If the
opposite is true, as is most common in avian animals/
birds, the nomenclature changes to ZZ, ZW, to apply to
the closest available letters in the English alphabet.
Indeed, this choice was meant to stress the evident ana-
logues between these two major chromosomal sex deter-
mination strategies and their potential common
evolutionary history. Although this issue remains debata-
ble to this date, with various researchers presenting argu-
ments in favor or against this generalized unifying theory,
recent data appears to suggest a common background for
XY and ZW, with episodes of genomic transition among
them [30-33]. In particular, it seems that there is a degra-
dation process for both Y and W and a significant inter-
species conservation rate for both X and Z. Although X
and Z structures and genomic sequences are completely
different, their presence in closely related species (e.g.
fish) in highly conserved form and the knowledge that
single gene sexual dimorphism has been detected in some
organisms of the same group leads to the hypothesis that
there might indeed be a common ancestry for all sex chro-
mosomes [30].
Regardless of the answer to whether a common origin for
all gonosomes may indeed have existed, it is true that the
necessity for dosage compensation has so far been proven
for all animals exhibiting chromosomal sex-specific varia-
tion and submitted to full genomic analysis, e.g. nema-
todes, flies and mammals. Therefore, it is reasonable to
assume that a similar process might be present in other
animals with an XX/XY or ZZ/ZW chromosomal sex deter-
mination system, which could also generate genetic dose
inequality between the sexes. However, this may be exam-
ined only if a full genomic analysis is available for these
species, a process which may require a few extra years. ThisReproductive Biology and Endocrinology 2008, 6:12 http://www.rbej.com/content/6/1/12
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is, for example, the case with reptiles, the genomic analy-
sis of which has only recently been proposed as a fully
operational project [31]. Therefore, until data becomes
available for these species as well, the existence of dosage
compensation in animals other than the model organisms
already examined in detail (basically Caenorhabditis ele-
gans, Drosophila melanogaster and Mus musculus) largely
remains a supposition and is, therefore, impossible to dis-
cuss further, at present, in the context of a review paper.
A few recent publications have enriched the literature with
insight as to the presence of dosage compensation in
other animals as well. In particular, studies performed in
chicken and zebra finch demonstrate that dosage com-
pensation must occur to some extend in these species as
well, but it doesn't achieve the equality in gene expression
observed in other animals with a chromosomal sex deter-
mination pattern [33-35]. This is most surprising, since,
even in the case of humans, gene expression in males and
females is comparable for both autosomes and gono-
somes, despite the existence of genes that escape X chro-
mosome inactivation, contrary to birds, where the
expression rate is profoundly different in the two above-
mentioned cases [35-38]. The mechanism of dosage com-
pensation in birds, itself, remains unknown, with several
candidate players (e.g. non-coding RNAs, similar to rox)
suggested, but no actual proof concerning their potential
role in the process reported in the literature so far [33-35].
Dosage compensation in mammals: X 
chromosome inactivation
In mammals, sex is determined by the presence of the Y
chromosome and, more specifically, its male specific
region (MSY), a non-recombining region (apart from self
recombining repeats within the chromosome) organized
around the major sex determinant gene. i.e. SRY (sex
determining region of the Y chromosome). Based on com-
parative genetic analysis, scientists have shown that the
SRY is common to all mammals and, most probably, con-
stitutes the initial event in a series of successive phenom-
ena (recombination failure, sequence duplication,
genomic transfer, translocation) that led to gradual X-Y
distinction, from a pair of identical autosomes to their
current form. As a result of these genomic variations, the
Y chromosome has gradually deteriorated, maintaining
only minimal homology to the X chromosome, mainly
detected in the two distant arms of the chromosomes,
which constitute the so called pseudo-autosomal regions
1 and 2 (symbolized as PAR1 and PAR2, respectively) [36-
38]. On the other hand, this gradual deterioration has
lead to a considerable excess of genetic information in XX
females, bearing two X chromosomes, compared to XY
males, with a single copy. The means to overcome this
inequality has been developed early in mammalian evolu-
tion in the form of the effective transcriptional silencing
of almost the whole of all but one X chromosomes, in all
diploid cells of marsupial and eutherian mammals. This
process has been originally described by Mary Lyon in
mice and is now known as "the Mary Lyon hypothesis of
X chromosome inactivation" or simply "Lyonization
hypothesis," a principle that continues to be accepted
with minimal reforms after almost 50 years from its initial
publication [38-40].
In the original version, the Lyon hypothesis referred to X
chromosome inactivation in mice, proposing the follow-
ing basic characteristics:
1. X chromosome inactivation is catholic, in the sense that
it refers to the translational silencing of all the content of
one X chromosome in every diploid cell of a typical 46, XX
female, with no exception. In subsequent years, this con-
cept was further supported by evidence that the inactive X
chromosome actually underwent a rapid transformation
to structural heterochromatin (Barr Body).
2. X chromosome inactivation is random in somatic tis-
sues, i.e. in each diploid cell of normal females either the
paternal or the maternal copy will be inactivated. How-
ever, this choice is repeated in all derivative cells in a con-
stant manner, i.e. the inactivation motif is retained in a
clonal way. This, effectively, justifies the characterization
of females as functional mosaics of X-linked genes, in case
the information coded in the alleles of the same locus in
each X chromosome is different.
3. X chromosome inactivation occurs very early in devel-
opment. Indeed, the period of initiation of X inactivation
has been proposed to correspond to the end of the first
week of gestation, which proves its necessity for normal
embryonic growth and subsequent tissue differentiation
and commitment to specific cell lineages.
In the years that followed the followed the initial descrip-
tion of the Lyon hypothesis, a number of researchers
enriched the literature with information on the molecular
mechanism of X chromosome inactivation and its varia-
tions among different mammalian species. Thus, we now
know, that some genes on the X chromosome escape/
evade inactivation and, therefore, this process is not truly
complete, as Mary Lyon believed. At least 35 such escapees
have been described so far in the human X chromosome
and their distribution appears to be non-random,
although its exact significance hasn't been understood yet.
Moreover, despite the initial belief that X chromosome
inactivation is by definition a random selection phenom-
enon, subsequent research has revealed that this is only
partially true [36-40].Reproductive Biology and Endocrinology 2008, 6:12 http://www.rbej.com/content/6/1/12
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For instance, in monotremes, the non homologous sec-
tion of the gonosomes is restricted to the area around the
SRY gene and, thus, only this section is submitted to inac-
tivation/transcriptional down-regulation. In marsupials,
X chromosome inactivation is a more generalized phe-
nomenon, but the choice of the X to be inactivated is not
random [40]. In fact, it seems to follow an epigenetic
imprinting principle, according to which, the X of pater-
nal origin is the one marked as the target of the inactiva-
tion mechanism, while the maternal one remains fully
active. Naturally, this operation limits the capacity to pro-
mote genetic variation, since the ability to co-express dif-
ferent alleles in a mosaic fashion is only available in
random-selection systems, as is the case in eutherian
mammals. More interestingly, in some of the latter, such
as rodents (mice), X chromosome inactivation appears to
maintain a transient pattern, with somatic tissues of the
embryo featuring random choice of the inactive X, while
the extraembryonic tissues continue to demonstrate an
imprinted pattern [38].
In an attempt to explain this paradox, most scientists seem
to conclude that X chromosome inactivation is an adap-
tive mechanism that has developed gradually over centu-
ries of evolutionary history, initially using basic molecular
tools. The latter were gradually enriched and updated to
more sophisticated and complex patterns of interaction. If
this is indeed accurate (and the study of various mammals
along their evolutionary tree, focusing on X-Y structure
and dosage compensation pattern, appears to validate this
concept so far) it would imply that X chromosome inacti-
vation appeared as an adaptive response to the increasing
need for a countermeasure to gene inequality among X
and the deteriorating Y chromosome. This process may
have initiated using basic translational control means
ubiquitously available, i.e. functional non-coding RNAs
(ribozyme equivalents) and histone modification epige-
netic regulatory elements (mostly acetylation and methyl-
ation). Indeed, the preservation of these elements in
major regulatory/adaptive reactions (including dosage
compensation itself) in a variety of evolutionary distinct
species appears to validate this theory. Non-coding RNAs,
for instance, are present in birds, although their role is yet
unclear. In humans, they are also involved in genomic
imprinting, as has been revealed by the study of relevant
diseases, such as the Prader-Willi syndrome, Beckwieth-
Wiedermann syndrome and Mc Cune-Albright syndrome.
Within the context of cell economy, the selection mecha-
nism (i.e. which X will be silenced) may also be associated
with these common cellular regulatory tools. The role of
non-coding RNAs, such as Tsix, is clear in the case of mice,
where it appears to influence the production and availa-
bility of the major regulator of X inactivation, i.e. Xist. In
the extra-embryonic tissues, the process is also operating
via methylation imprinting of X-linked sites, such as the
DXPas locus. The development of a more advanced, ran-
dom selection model is viewed in this approach as a later
evolutionary event and, for this reason, it is only partially
observed in rodents and it has completely removed
imprinting-based selection only in primates and humans,
where the equivalent of Tsix, i.e. TSIX, has no reported
function [37-41].
Still, even in the latter, random choice is not an infallible
process and several cases of non random selection have
been described, with a possible link to the onset of various
diseases. This is known as the skewing principle for X
chromosome inactivation or skewed X inactivation and it
remains a debatable issue both in terms of etiology (dis-
ruption of X chromosome integrity is only detected in a
minority of subjects) as well as succinct evaluation of its
clinical significance (if any) [38-42].
X chromosome inactivation pathway: A three 
step silencing operation
Although, as previously described, X chromosome inacti-
vation is common to all mammals, it has been described
in greater detail in mice, where it was also initially discov-
ered. Subsequent studies in other mammals are, thus,
mainly aiming to examine the presence and role of vari-
ous mediators already known to participate in the process
in rodents. For this reason, the model further described is
completely accurate only for mice, while additional spe-
cific references are also made to humans wherever rele-
vant data is available.
X chromosome inactivation is a process that rapidly
results in the loss of expression of almost all genes located
on the targeted chromosome (indeed, minimal expres-
sion of genes is detected prior to inactivation on both X
chromosomes, including, most interestingly, genes
directly associated with the inactivation process itself,
such as Xist). This observation implies that there must be
an initial phase when the number of autosomes and
gonosomes is somehow counted and the choice of the X
to be inactivated is made (based on either imprinting or
random selection). Nevertheless, it is also a stable process,
because, once established, it is retained in a most reliable
manner in all future tissues. Therefore, a molecular model
must explain a)how inactivation commences early during
fetal development b)how this initial signal rapidly
spreads along the whole X chromosome (but also evading
some specific sites, as previously reported) and c)how this
mechanism is stabilized, so that it can securely and accu-
rately extend to all derivative cells. These three distinct
phenomena are usually described as the three stages of X
chromosome inactivation, i.e. initiation (including chro-
mosome counting and inactive X selection), expansion
(including inactivation message expansion, chromosomeReproductive Biology and Endocrinology 2008, 6:12 http://www.rbej.com/content/6/1/12
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coating and gene silencing) and maintenance (epigenetic
regulation/chromatin modification aiming to maintain
the inactive state) [41,42].
The initiation stage is characterized by the selection of the
X chromosome to be inactivated. Although the exact
mechanism remains to be determined, it seems that the
process is based on the creation of an initiation complex,
which includes a blocking factor (BF) coded by one or
more autosomes (thus serving as an indicator of auto-
somal chromosome number in the cell) and a binding site
for it on chromosome X. The latter area is an indirect
means to determine the number of X chromosomes and is
therefore described as the counting element (CE). In
organisms with random X chromosome inactivation, the
creation of the initiation complex is viewed as a competi-
tive phenomenon, where the quantity of BF in diploid
cells is always enough to bind to all available CEs but one.
In this case, in normal XX females one X is targeted for
inactivation while in normal XY males none. As was pre-
viously mentioned, neither the BF nor the CE have been
accurately detected in any mammal to this date and, there-
fore, the initiation complex theory remains to be verified
[43]. A number of more complicated events, such as the
homologous pairing of X chromosomes may be also sig-
nificant in the initiation of this process.
The first signal of a commitment towards X chromosome
inactivation is the stable expression of Xist  (X inactive
chromosome specific transcript). This gene is located on
the X chromosome, in the section which includes most X
inactivation-associated regulatory elements usually
described as X inactivation center. The gene produces a
non-translated functional RNA, which is only temporarily
expressed in pre-inactivation X chromosomes, while its
stable persistent expression characterizes the inactive X
only [see Figure 2]. This is an interesting exception to the
general rule by which the opposite is usually true, i.e. the
largest number of X-linked genes are only active on the
non-inactivated X. Since the period of Xist parallel expres-
sion on all Xs is only minimal, it is considered as a marker
of X inactivation widely used in the literature. From a
mechanistic point of view, it appears that the BF-CE com-
plex, if indeed present, must somehow hinder the further
presence of Xist RNA by acting at the promoter region or
other transcription-associated regulatory elements [43-
46].
In animals with non-random X inactivation, a number of
additional factors are involved in X selection [47]. For
example, in mice, such loci include the Xce and Xite
regions, also known as choice elements. If inactivation
follows an imprinted pattern, as is the case in marsupial
mammals or extraembryonic rodent cells, then there must
also be a methylation variation at the epigenetic level
[47], occurring either around the Xist locus or around the
Tsix, an area (XPas 34) that produces a complementary
antisense transcript thought to directly or indirectly
hinder Xist action in mice. On the other hand, it should be
noted that data available for human X inactivation is
more limited, but it verifies the presence of both Xist and
Tsix analogues, of which the first retains a crucial function,
while the possible contribution of the second is still a con-
troversial issue. No other imprinting or choice elements
are known in humans, acting either in cis or in trans [48-
50].
The initiation stage of XCI Figure 2
The initiation stage of XCI.Reproductive Biology and Endocrinology 2008, 6:12 http://www.rbej.com/content/6/1/12
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The second or expansion stage of X inactivation is charac-
terized by the rapid coating of the X chromosome chosen
to be inactivated by Xist  RNA. This phenomenon is
described as spreading reaction and covers all the X, apart
from the two distant pseudoautosomal regions. It is based
on a gradual expansion principle, according to which, Xist
RNA binds to specific regions distributed non-symmetri-
cally along the X chromosome. These regions are evolu-
tionary conserved, non-coding sequences (Line1
sequences) and they may be a direct target for Xist RNA or
part of a larger complex, also involving protein interac-
tion, that remains to be detected [46]. The coating process
results in effective initial genetic silencing, excluding only
few genes along the chromosome that do not seem to
demand dosage compensation [see Figure 3]. A compara-
tive presentation of the basic features of both roX and Xist
RNAs is provided in Table 1.
The final inhibition of further gene expression and the
structural transition towards heterochromatin formation
(Barr body creation) is the object of the third and last
stage in X inactivation, the maintenance stage [see Figure
4]. This is an almost exclusive epigenetic regulation phase,
involving extensive DNA methylation in CPG islets, as
well as histone hypermethylation and hypoacetylation
(Lysine). Finally, macrohistone formation is also a com-
mon observation [51-54]. In the process of maintenance
of X inactivation in mice, several other genes have been
proven to be major players, including members of the
Polycomb group (e.g. eed), the product of which is a medi-
ator participating in histone methyltion and deacetyla-
tion. All the above interactions result in a differentiated
biochemical profile and three dimensional space distribu-
tion, which makes the interaction of the inactive X chro-
mosome with RNA polymerases almost impossible, thus
establishing a stable and complete genetic silencing pat-
tern. The use of chromatin modification strategies to
achieve massive gene expression regulation is a classic
motif in nature, also observed in a variety of species and
in different normal and pathological scenarios [55-58]
and details for its use in dosage compensation may be
found in Table 2.
Comparing the RNAs
Having reviewed the major points of dosage compensa-
tion in two largely distant species, Drosophila melanogaster
and humans, one significant detail seems to immediately
draw attention: the implication of non-translatable RNAs
as a means to target the appropriate chromosomes [59-
63].
Indeed, both roX and Xist RNAs exhibit a unique function
as far as RNA molecules are concerned, being exclusively
associated with the field of dosage compensation [62-64].
It also seems interesting to note that, although it is
unlikely that these two may share a common ancestor
RNA molecule performing the same role, since the two
species were separated before the emergence of heterog-
amety and even their sex chromosomes derive from differ-
ent sets of autosomes, they exhibit some intriguing
similarities. To begin with, they are both excellent exam-
ples of RNA molecules that are submitted to the processes
of splicing and polyadenylation, when neither of them is
allowed to exit the cell nucleus or has an identifiable read-
ing frame that may allow their translation into a protein
molecule. They are also both the only RNA molecules that
have been described to date as being capable of interact-
ing with and spreading across the chromosome that
The expansion stage of XCI Figure 3
The expansion stage of XCI.Reproductive Biology and Endocrinology 2008, 6:12 http://www.rbej.com/content/6/1/12
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Table 1: Non-coding RNAs in dosage compensation
Feature roX RNA Xist RNA
Number of genes 2 1
Site of production X chromosome X chromosome
Length 3.7 kb (roX1) 0.5–1.2 kb (roX2) 19.3 Kb
Expression duration Retained over time Transient
Sex specific expression Yes Yes
Role in compensasome-condensasome formation Yes Possible
Necessity Initiation, Maintenance Initiation, Spreading
Expansion in cis Limited Along the chromosome
Expansion in trans Yes Yes
Coating/Spreading Limited (debatable) Definite, large scale
Table summarizing the key features of the two major types of non-coding RNAs involved with dosage compensation.
The maintenance stage of XCI Figure 4
The maintenance stage of XCI.
Table 2: Epigenetic phenomena in dosage compensation
Feature Drosophila Mammals
Histone Acetylation H4Ac16, special histone isoform acetylation Hypoacetylation
CpG Methylation Not described to date Hypermethylation
Histone Methylation Not described to date Hypermethylation
Histone Phosphorylation Assumed (kinase action) Not described to date
Macrohistone Formation Not described to date Yes
Selection Pattern No need for selection Imprinted/Random
Comparison of epigenetic phenomena involved in dosage compensation in the fruitfly and mammals.Reproductive Biology and Endocrinology 2008, 6:12 http://www.rbej.com/content/6/1/12
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houses their gene locus. Moreover, this ability is retained
even when the relevant gene is inserted in another chro-
mosome, in which case they exhibit the same behavior by
interacting with the new chromosome, limited as that
may be in the case of roX, or even Xist, if Line-1 binding
sequences are missing [see Figure 5]. In addition, both
RNAs are apparently capable of specifically exempting cer-
tain genes from the delicate chromosome silencing proc-
ess [64-66].
However, there are also important differences that one
cannot justifiably disregard. For instance, although both
RNAs bind to active chromosomes, Xist RNA results in its
transcriptional suppression (i.e. inhibition of gene expres-
sion – gene silencing) while, on the other hand, roX RNA
permits gene expression. Mammalian Xist RNA can only
act in cis, since the entire process of X inactivation is meant
to be engaged in only one of the two X chromosomes.
Allowing the Xist the ability to act in trans would have
resulted in loss of control over the entire selection process.
On the other hand, the roX RNAs have been long known
to be capable of both in trans accumulation and in cis
spreading with the aid of the dosage compensation com-
plex and so long as the appropriate entry sites are availa-
ble. Whether that is a result of having to ensure that the
entirety of the single X chromosome will be properly
involved or a mere by-product of the fact that there is no
need to ensure the process will only be constrained in one
of two X chromosomes remains unsure. Besides, one can-
not forget that, due to their very own nature, the two roX
RNA were only meant to spread from the circa 35 major
entry sites across a mere total of 25 Mb that consist the
Drosophila's X chromosome, whereas human Xist RNA has
to spread across an area of more than 100 Mb from the
single location of its production site [64-66].
Common elements, common strategies: 
Perhaps common history as well?
The description of the basic dosage compensation strate-
gies in this review has emphasized some key similarities
between the two model organisms mostly analyzed,
namely the common fruitfly and the mouse [see Table 3].
These may of course be attributed to chance without any
further biological or even scientific interest in general.
However, the use of so compatible strategies in species as
evolutionary distant as these still appears to be a most
remarkable phenomenon [67-69]. When one also takes
into account the fact that non-coding RNAs are consid-
ered by evolutionary biology the most primitive kind of
functional machinery devised in the cell (even before the
large scale use of protein enzymes) and that epigenetic
regulation at the level of histones is an almost universal
biological principle (from all eukaryotic cells, only sper-
matozoa lack histones as a result of protaminosis), it may
be reasonably assumed that this retained cell economy
may not be simply attributed to chance. Naturally, the
current lack of knowledge concerning sex determination
in various species across the evolutionary tree and the
even greater lack of data on dosage compensation makes
the accurate development of evolutionary hypotheses,
supported by solid evidence, impossible at present. How-
ever, several research projects are in progress and their
Table 3: Dosage compensation mechanisms: an overview of their basic characteristics
Feature Drosophila Mammals
Gene regulation result Hypertranscription Transcriptional silencing
Genes escaping effect Different cases already established Established (humans/mice)
Clonality Assumed Established
Outcome in case of Quantitative 
Chromosomal Abnormalities
Sex reversal or lethality (sex determined by the 
ratio of autosomes to gonosomes)
All but one X are inactivated in diploid cells 
(X-1 rule)
Comparison of the basic characteristics of dosage compensation in flies and mammals.
While both roX and Xist retain the ability to initiate dosage  compensation when transferred to an autosome, Xist has the  potency to spread along the entire chromosome, whereas  roX has only been known to affect neighboring genes Figure 5
While both roX and Xist retain the ability to initiate dosage 
compensation when transferred to an autosome, Xist has the 
potency to spread along the entire chromosome, whereas 
roX has only been known to affect neighboring genes. How-
ever, even in the case of Xist RNA, the ability to spread along 
an entire chromosome depends on both the number of gene 
copies and the presence of an adequate number of booster 
elements (i.e. binding sequences, such as Line 1).Reproductive Biology and Endocrinology 2008, 6:12 http://www.rbej.com/content/6/1/12
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findings will aid considerably this task, since the discovery
of similar dosage compensation patterns in other animals,
such as reptiles or birds, will support the argument of a
common evolutionary history for all these species, at least
with regard to sex chromosome origin [67-69].
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